{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:52:22Z","timestamp":1791179542320,"version":"4.1.0"},"reference-count":151,"publisher":"Impact Journals, LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2011,3,31]]},"DOI":"10.18632\/oncotarget.234","type":"journal-article","created":{"date-parts":[[2015,9,16]],"date-time":"2015-09-16T21:52:31Z","timestamp":1442440351000},"page":"122-134","source":"Crossref","is-referenced-by-count":105,"title":["Recent Advances in Anti-Angiogenic Therapy of Cancer"],"prefix":"10.18632","volume":"2","author":[{"given":"Rajeev S.","family":"Samant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalita A.","family":"Shevde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2011,3,7]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1046\/j.1523-1755.1998.06701.x","article-title":"Development and differentiation of endothelium","volume":"67","author":"Risau","year":"1998","journal-title":"Kidney Int Suppl"},{"key":"2","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1161\/01.RES.82.8.926","article-title":"Angiogenesis is coming of age","volume":"82","author":"Risau","year":"1998","journal-title":"Circ Res"},{"key":"3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0098-2997(02)00096-1","article-title":"Intussusceptive angiogenesis--the alternative to capillary sprouting","volume":"23","author":"Djonov","year":"2002","journal-title":"Mol Aspects Med"},{"key":"4","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/dvdy.20184","article-title":"Intussusceptive angiogenesis: Its emergence, its characteristics, and its significance","volume":"231","author":"Djonov","year":"2004","journal-title":"Dev Dyn"},{"key":"5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4419-8871-3_1","article-title":"Vasculogenesis and angiogenesis","volume":"117","author":"Patan","year":"2004","journal-title":"Cancer Treat Res"},{"key":"6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF01787020","article-title":"Interactions between cancer cells and the microvasculature: A rate-regulator for metastasis","volume":"7","author":"Honn","year":"1989","journal-title":"Clin Exp Metastasis"},{"key":"7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/BF00409698","article-title":"Vascularization of tumors: A review","volume":"103","author":"Shubik","year":"1982","journal-title":"J Cancer Res Clin Oncol"},{"key":"8","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3233\/BIR-1984-21408","article-title":"Factors influencing the neovascularization of experimental tumours","volume":"21","author":"van den Berg-Blok","year":"1984","journal-title":"Biorheology"},{"key":"9","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2174\/156800907783220462","article-title":"Molecular and cellular regulators of cancer angiogenesis","volume":"7","author":"Roufogalis","year":"2007","journal-title":"Curr Cancer Drug Targets"},{"key":"10","first-page":"556","article-title":"Tumour's angiogenesis--the function of vegf and bfgf in colorectal cancer","volume":"57","author":"Dabrowski","year":"2002","journal-title":"Ann Univ Mariae Curie Sklodowska [Med]"},{"key":"11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/sonc.2002.37263","article-title":"Role of angiogenesis in tumor growth and metastasis","volume":"29","author":"Folkman","year":"2002","journal-title":"Semin Oncol"},{"key":"12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0092-8674(94)90200-3","article-title":"Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma","volume":"79","author":"Folkman","year":"1994","journal-title":"Cell"},{"key":"13","doi-asserted-by":"crossref","first-page":"12337","DOI":"10.1073\/pnas.2031337100","article-title":"Angiogenesis impairment in id-deficient mice cooperates with an hsp90 inhibitor to completely suppress her2\/neu-dependent breast tumors","volume":"100","author":"Benezra","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"14","doi-asserted-by":"crossref","first-page":"13543","DOI":"10.1073\/pnas.2230238100","article-title":"Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis","volume":"100","author":"Desprez","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"15","doi-asserted-by":"crossref","first-page":"19506","DOI":"10.1073\/pnas.0709185104","article-title":"Id genes mediate tumor reinitiation during breast cancer lung metastasis","volume":"104","author":"Massague","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"16","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/nm1101-1194","article-title":"Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth","volume":"7","author":"Rafii","year":"2001","journal-title":"Nat Med"},{"key":"17","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nrc1693","article-title":"Opinion: Emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis","volume":"5","author":"Cao","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"18","first-page":"1406","article-title":"Expanding therapeutic targets in bladder cancer: The pi3k\/akt\/mtor pathway","volume":"90","author":"Hansel","journal-title":"Lab Invest"},{"key":"19","first-page":"881","article-title":"Pseudo-active sites of protease domains: Hgf\/met and sonic hedgehog signaling in cancer","volume":"391","author":"Lazarus","journal-title":"Biol Chem"},{"key":"20","doi-asserted-by":"crossref","first-page":"22888","DOI":"10.1074\/jbc.M109.021949","article-title":"The hedgehog pathway transcription factor gli1 promotes malignant behavior of cancer cells by up-regulating osteopontin","volume":"284","author":"Shevde","year":"2009","journal-title":"J Biol Chem"},{"key":"21","unstructured":"Das, Samant, Shevde. Hedgehog signaling induced by breast cancer cells promotes osteoclastogenesis and osteolysis. J Biol Chem."},{"key":"22","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1158\/0008-5472.CAN-08-3402","article-title":"Secreted frizzle-related protein 2 stimulates angiogenesis via a calcineurin\/nfat signaling pathway","volume":"69","author":"Klauber-Demore","year":"2009","journal-title":"Cancer Res"},{"key":"23","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/ijc.24276","article-title":"Nmi (n-myc interactor) inhibits wnt\/beta-catenin signaling and retards tumor growth","volume":"125","author":"Samant","year":"2009","journal-title":"Int J Cancer"},{"key":"24","first-page":"24686","article-title":"Dnajb6 induces degradation of beta-catenin and causes partial reversal of mesenchymal phenotype","volume":"285","author":"Samant","journal-title":"J Biol Chem"},{"key":"25","first-page":"233","article-title":"Cox-2 as a target for cancer chemotherapy","volume":"62","author":"Mandal","journal-title":"Pharmacol Rep"},{"key":"26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1158\/0008-5472.CAN-07-2126","article-title":"Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms","volume":"68","author":"Kundu","year":"2008","journal-title":"Cancer Res"},{"key":"27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000468621","article-title":"Plasminogen activators and matrix metalloproteinases in angiogenesis","volume":"49","author":"Rifkin","year":"1996","journal-title":"Enzyme Protein"},{"key":"28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1196\/annals.1415.019","article-title":"Adhesive and proteolytic phenotype of migrating endothelial cells induced by thymosin beta-4","volume":"1112","author":"Cierniewska-Cieslak","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"29","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.yexcr.2005.11.015","article-title":"Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action","volume":"312","author":"Folkman","year":"2006","journal-title":"Exp Cell Res"},{"key":"30","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1600-0463.2004.apm11207-0809.x","article-title":"Endogenous angiogenesis inhibitors","volume":"112","author":"Folkman","year":"2004","journal-title":"Apmis"},{"key":"31","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1471-4892(02)00184-4","article-title":"Drug inhibition of angiogenesis","volume":"2","author":"Harris","year":"2002","journal-title":"Curr Opin Pharmacol"},{"key":"32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/1534735405285562","article-title":"Targeting angiogenesis with integrative cancer therapies","volume":"5","author":"Sagar","year":"2006","journal-title":"Integr Cancer Ther"},{"key":"33","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0092-8674(94)90187-2","article-title":"The implications of angiogenesis for the biology and therapy of cancer metastasis","volume":"79","author":"Ellis","year":"1994","journal-title":"Cell"},{"key":"34","first-page":"753","article-title":"Anti-angiogenic therapies in cancer: Achievements and open questions","volume":"94","author":"Mutter","year":"2007","journal-title":"Bull Cancer"},{"key":"35","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.2174\/138161206777698756","article-title":"Angiogenesis inhibitors: Perspectives for medical, surgical and radiation oncology","volume":"12","author":"Verheul","year":"2006","journal-title":"Curr Pharm Des"},{"key":"36","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrc905","article-title":"Clinical translation of angiogenesis inhibitors","volume":"2","author":"Folkman","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"37","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"Folkman","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"38","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1445-2197.2008.04712.x","article-title":"Selective targeting of the tumour vasculature","volume":"78","author":"Christophi","year":"2008","journal-title":"ANZ J Surg"},{"key":"39","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1200\/JCO.2005.02.477","article-title":"Phase i\/ii trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the her-1\/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer","volume":"23","author":"Sandler","year":"2005","journal-title":"J Clin Oncol"},{"key":"40","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1200\/JCO.2007.12.3026","article-title":"Phase ii study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer","volume":"25","author":"Sandler","year":"2007","journal-title":"J Clin Oncol"},{"key":"41","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1586\/14737140.8.5.689","article-title":"Bevacizumab for the treatment of advanced non-small-cell lung cancer","volume":"8","author":"Manegold","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"42","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1053\/j.seminoncol.2006.08.005","article-title":"Bevacizumab in combination with chemotherapy: First-line treatment of patients with metastatic colorectal cancer","volume":"33","author":"Hochster","year":"2006","journal-title":"Semin Oncol"},{"key":"43","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000195884","article-title":"Clinical benefit of new targeted agents in phase i trials in patients with advanced colorectal cancer","volume":"76","author":"Kaye","year":"2009","journal-title":"Oncology"},{"key":"44","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3816\/CBC.2008.n.048","article-title":"Evolution of bevacizumab-based therapy in the management of breast cancer","volume":"8","author":"Jahanzeb","year":"2008","journal-title":"Clin Breast Cancer"},{"key":"45","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/sj.bjc.6604741","article-title":"Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced er- and\/or pgr-positive breast cancer: Clinical and biological activity","volume":"99","author":"Colleoni","year":"2008","journal-title":"Br J Cancer"},{"key":"46","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/PPO.0b013e3181867bd6","article-title":"Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas","volume":"14","author":"Yung","year":"2008","journal-title":"Cancer J"},{"key":"47","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.4161\/cbt.4.12.2315","article-title":"How avastin potentiates chemotherapeutic drugs: Action and reaction in antiangiogenic therapy","volume":"4","author":"Blagosklonny","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"48","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1365-2141.2008.07372.x","article-title":"Antiangiogenesis in haematological malignancies","volume":"143","author":"Gehr","year":"2008","journal-title":"Br J Haematol"},{"key":"49","first-page":"1523","article-title":"Neutralizing antibodies against epidermal growth factor and erbb-2\/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors","volume":"151","author":"Kerbel","year":"1997","journal-title":"Am J Pathol"},{"key":"50","unstructured":"Erbitux\u00ae (cetuximab), ImClone Systems, Incorporated; Bristol-Myers Squibb Company, Princeton, NJ, [prescribing information]:"},{"key":"51","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/sj.bjc.6603018","article-title":"Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: A single centre phase ii trial","volume":"94","author":"Tonini","year":"2006","journal-title":"Br J Cancer"},{"key":"52","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3816\/CCC.2006.n.013","article-title":"Efficacy and safety of cetuximab\/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: A clinical practice setting, multicenter experience","volume":"5","author":"Barone","year":"2006","journal-title":"Clin Colorectal Cancer"},{"key":"53","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1200\/JCO.2001.19.13.3234","article-title":"Phase i study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer","volume":"19","author":"Waksal","year":"2001","journal-title":"J Clin Oncol"},{"key":"54","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Ang","year":"2006","journal-title":"N Engl J Med"},{"key":"55","doi-asserted-by":"crossref","first-page":"31182","DOI":"10.1074\/jbc.M506591200","article-title":"Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase","volume":"280","author":"Rodemann","year":"2005","journal-title":"J Biol Chem"},{"key":"56","first-page":"871","article-title":"Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck","volume":"3","author":"Occelli","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"57","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1200\/JCO.2005.04.3547","article-title":"Phase i\/ii study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck","volume":"24","author":"Harstrick","year":"2006","journal-title":"J Clin Oncol"},{"key":"58","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1200\/JCO.2000.18.4.904","article-title":"Phase i studies of anti-epidermal growth factor receptor chimeric antibody c225 alone and in combination with cisplatin","volume":"18","author":"Mendelsohn","year":"2000","journal-title":"J Clin Oncol"},{"key":"59","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1188\/08.CJON.30-32","article-title":"Review of panitumumab: A targeted therapy","volume":"12","author":"Winkeljohn","year":"2008","journal-title":"Clin J Oncol Nurs"},{"key":"60","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1634\/theoncologist.12-5-577","article-title":"Fda drug approval summary: Panitumumab (vectibix)","volume":"12","author":"Pazdur","year":"2007","journal-title":"Oncologist"},{"key":"61","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1158\/1078-0432.CCR-07-1354","article-title":"U.S. Food and drug administration approval: Panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens","volume":"14","author":"Pazdur","year":"2008","journal-title":"Clin Cancer Res"},{"key":"62","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3816\/CCC.2007.n.011","article-title":"Panitumumab with irinotecan\/leucovorin\/5-fluorouracil for first-line treatment of metastatic colorectal cancer","volume":"6","author":"Hecht","year":"2007","journal-title":"Clin Colorectal Cancer"},{"key":"63","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/cncr.22915","article-title":"Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer","volume":"110","author":"Meropol","year":"2007","journal-title":"Cancer"},{"key":"64","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","article-title":"Open-label phase iii trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer","volume":"25","author":"Amado","year":"2007","journal-title":"J Clin Oncol"},{"key":"65","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1517\/14712598.6.11.1229","article-title":"Panitumumab in colon cancer: A review and summary of ongoing trials","volume":"6","author":"Hecht","year":"2006","journal-title":"Expert Opin Biol Ther"},{"key":"66","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1158\/1541-7786.MCR-07-2131","article-title":"Effects of palifermin on antitumor activity of chemotherapeutic and biological agents in human head and neck and colorectal carcinoma xenograft models","volume":"6","author":"Borges","year":"2008","journal-title":"Mol Cancer Res"},{"key":"67","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ijrobp.2008.06.1490","article-title":"Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer","volume":"72","author":"Harari","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"68","first-page":"3","article-title":"A testing algorithm for determination of her2 status in patients with breast cancer","volume":"32","author":"Cate","year":"2002","journal-title":"Ann Clin Lab Sci"},{"key":"69","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.ejca.2008.09.013","article-title":"Her2-positive breast cancer: Herceptin and beyond","volume":"44","author":"Esteva","year":"2008","journal-title":"Eur J Cancer"},{"key":"70","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1038\/sj.onc.1210379","article-title":"Trastuzumab: Triumphs and tribulations","volume":"26","author":"Esteva","year":"2007","journal-title":"Oncogene"},{"issue":"1","key":"71","first-page":"14","article-title":"Her-2 breast assay, linked to herceptin, wins fda's okay","volume":"12","author":"Graziano","year":"1998","journal-title":"CAP Today"},{"key":"72","unstructured":"Monoclonal antibody approved for metastatic breast cancer. Oncology (Williston Park). 1998; 12:1727."},{"key":"73","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0140-6736(99)00430-4","article-title":"Response of metastatic breast cancer to trastuzumab?","volume":"355","author":"Miles","year":"2000","journal-title":"Lancet"},{"key":"74","first-page":"9","article-title":"A prospective, non-randomized phase-ii trial of trastuzumab and capecitabine in patients with her2 expressing advanced pancreatic cancer","author":"Geissler","year":"2009","journal-title":"BMC Surg"},{"key":"75","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijgo.2008.04.008","article-title":"Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing her2\/neu","volume":"102","author":"Pecorelli","year":"2008","journal-title":"Int J Gynaecol Obstet"},{"key":"76","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1021\/tx700310x","article-title":"Solamargine enhances her2 expression and increases the susceptibility of human lung cancer h661 and h69 cells to trastuzumab and epirubicin","volume":"21","author":"Kuo","year":"2008","journal-title":"Chem Res Toxicol"},{"key":"77","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1471-2407-4-59","article-title":"Her2 expression in cervical cancer as a potential therapeutic target","volume":"4","author":"Duenas-Gonzalez","year":"2004","journal-title":"BMC Cancer"},{"key":"78","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ctrv.2006.01.001","article-title":"Prognostic, predictive and therapeutic implications of her2 in invasive epithelial ovarian cancer","volume":"32","author":"De la Garza-Salazar","year":"2006","journal-title":"Cancer Treat Rev"},{"key":"79","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1634\/theoncologist.10-7-461","article-title":"Fda drug approval summary: Erlotinib (tarceva) tablets","volume":"10","author":"Pazdur","year":"2005","journal-title":"Oncologist"},{"key":"80","doi-asserted-by":"crossref","unstructured":"Erlotinib: Cp 358774, nsc 718781, osi 774, r 1415. Drugs R D. 2003; 4:243\u20138.","DOI":"10.2165\/00126839-200304040-00006"},{"key":"81","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1634\/theoncologist.2008-0108","article-title":"Bevacizumab and erlotinib: A promising new approach to the treatment of advanced nsclc","volume":"13","author":"Sandler","year":"2008","journal-title":"Oncologist"},{"key":"82","first-page":"1696","article-title":"Erlotinib\/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas","volume":"21","author":"Pazdur","year":"2007","journal-title":"Oncology (Williston Park)"},{"key":"83","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1517\/14656566.9.9.1595","article-title":"Erlotinib: The first biologic in the management of pancreatic cancer","volume":"9","author":"Saif","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"84","doi-asserted-by":"crossref","first-page":"7878","DOI":"10.1158\/1078-0432.CCR-08-0141","article-title":"A phase ii trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer","volume":"14","author":"Hudis","year":"2008","journal-title":"Clin Cancer Res"},{"key":"85","article-title":"Phase ii trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma","author":"Abbruzzese","year":"2009","journal-title":"J Clin Oncol"},{"key":"86","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1200\/JCO.2007.11.5154","article-title":"Randomized phase ii study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer","volume":"25","author":"McDermott","year":"2007","journal-title":"J Clin Oncol"},{"key":"87","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/annonc\/mdm452","article-title":"A phase ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients","volume":"19","author":"Delord","year":"2008","journal-title":"Ann Oncol"},{"key":"88","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/annonc\/mdn174","article-title":"Results from a monocentric phase ii trial of erlotinib in patients with metastatic prostate cancer","volume":"19","author":"Viens","year":"2008","journal-title":"Ann Oncol"},{"key":"89","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1158\/1078-0432.CCR-07-5112","article-title":"Phase i trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer","volume":"14","author":"Ferreira","year":"2008","journal-title":"Clin Cancer Res"},{"key":"90","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: A multikinase inhibitor for treating cancer","volume":"5","author":"Kelley","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"91","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1634\/theoncologist.2008-0185","article-title":"Sorafenib for the treatment of unresectable hepatocellular carcinoma","volume":"14","author":"Pazdur","year":"2009","journal-title":"Oncologist"},{"key":"92","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1158\/1078-0432.CCR-06-1249","article-title":"Sorafenib for the treatment of advanced renal cell carcinoma","volume":"12","author":"Pazdur","year":"2006","journal-title":"Clin Cancer Res"},{"key":"93","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.ejca.2008.06.028","article-title":"Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies","volume":"44","author":"Gore","year":"2008","journal-title":"Eur J Cancer"},{"key":"94","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00280-006-0376-5","article-title":"Sunitinib malate","volume":"60","author":"Deray","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"95","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1634\/theoncologist.12-1-107","article-title":"Food and drug administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma","volume":"12","author":"Pazdur","year":"2007","journal-title":"Oncologist"},{"key":"96","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1158\/1078-0432.CCR-06-2328","article-title":"Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma","volume":"13","author":"Pazdur","year":"2007","journal-title":"Clin Cancer Res"},{"key":"97","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1586\/14737140.9.1.143","article-title":"Early development of sunitinib in hepatocellular carcinoma","volume":"9","author":"Raymond","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"98","article-title":"Acute hepatic failure following monotherapy with sunitinib for ovarian cancer","author":"Bischoff","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"99","article-title":"Major response to sunitinib (sutene(r)) in metastatic malignant phyllodes tumor of breast","author":"Ro","year":"2008","journal-title":"Invest New Drugs"},{"key":"100","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1097\/JTO.0b013e318174e9be","article-title":"The current status and evolving role of sunitinib in non-small cell lung cancer","volume":"3","author":"Socinski","year":"2008","journal-title":"J Thorac Oncol"},{"key":"101","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1517\/14656566.8.14.2359","article-title":"Sunitinib","volume":"8","author":"Rini","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"102","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.bbrc.2003.09.132","article-title":"Role of pi3k\/akt\/mtor signaling in the cell cycle progression of human prostate cancer","volume":"310","author":"Shi","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"103","doi-asserted-by":"crossref","first-page":"23679","DOI":"10.1074\/jbc.M700563200","article-title":"The effects of mtor-akt interactions on anti-apoptotic signaling in vascular endothelial cells","volume":"282","author":"Briscoe","year":"2007","journal-title":"J Biol Chem"},{"key":"104","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2174\/156652405774641034","article-title":"Mammalian target of rapamycin as a therapeutic target in leukemia","volume":"5","author":"Albitar","year":"2005","journal-title":"Curr Mol Med"},{"key":"105","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.2174\/092986707781368423","article-title":"Targeting the phosphatidylinositol 3-kinase\/akt\/mammalian target of rapamycin module for acute myelogenous leukemia therapy: From bench to bedside","volume":"14","author":"Cocco","year":"2007","journal-title":"Curr Med Chem"},{"key":"106","doi-asserted-by":"crossref","unstructured":"Temsirolimus: Cci 779, cci-779, cell cycle inhibitor-779. Drugs R D. 2004; 5:363\u20137.","DOI":"10.2165\/00126839-200405060-00011"},{"key":"107","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1677\/erc.1.01170","article-title":"Combination therapy for treating breast cancer using antiestrogen, era-923, and the mammalian target of rapamycin inhibitor, temsirolimus","volume":"13","author":"Zhang","year":"2006","journal-title":"Endocr Relat Cancer"},{"key":"108","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000101008","article-title":"Cci-779 plus cisplatin is highly effective against human melanoma in a scid mouse xenotranplantation model","volume":"79","author":"Joukhadar","year":"2007","journal-title":"Pharmacology"},{"key":"109","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1038\/sj.jid.5700872","article-title":"Comparison of a treatment strategy combining cci-779 plus dtic versus dtic monotreatment in human melanoma in scid mice","volume":"127","author":"Joukhadar","year":"2007","journal-title":"J Invest Dermatol"},{"issue":"Suppl 5","key":"110","first-page":"S1","article-title":"Nccn task force report: Mtor inhibition in solid tumors","volume":"6","author":"Yen","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"111","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1158\/1535-7163.MCT-07-2408","article-title":"Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies","volume":"7","author":"Danielpour","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"112","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2362.2007.01892.x","article-title":"Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia","volume":"38","author":"Valent","year":"2008","journal-title":"Eur J Clin Invest"},{"key":"113","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jsbmb.2007.05.019","article-title":"Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer","volume":"106","author":"Dowsett","year":"2007","journal-title":"J Steroid Biochem Mol Biol"},{"key":"114","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3816\/CBC.2006.n.047","article-title":"Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer","volume":"7","author":"Cure","year":"2006","journal-title":"Clin Breast Cancer"},{"key":"115","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.4161\/cc.4.11.2159","article-title":"Mtor, a new therapeutic target in acute myeloid leukemia","volume":"4","author":"Payrastre","year":"2005","journal-title":"Cell Cycle"},{"key":"116","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1158\/1078-0432.CCR-07-1372","article-title":"A phase 2 clinical trial of deforolimus (ap23573, mk-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies","volume":"14","author":"Giles","year":"2008","journal-title":"Clin Cancer Res"},{"key":"117","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2174\/138920106779116865","article-title":"Bortezomib as an antitumor agent","volume":"7","author":"Anderson","year":"2006","journal-title":"Curr Pharm Biotechnol"},{"key":"118","doi-asserted-by":"crossref","first-page":"6294","DOI":"10.1158\/0008-5472.CAN-05-0686","article-title":"Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: Therapeutic implications","volume":"65","author":"Soengas","year":"2005","journal-title":"Cancer Res"},{"key":"119","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.leukres.2005.06.027","article-title":"Bortezomib (velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide","volume":"30","author":"Palumbo","year":"2006","journal-title":"Leuk Res"},{"key":"120","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1158\/1078-0432.CCR-06-0170","article-title":"United states food and drug administration approval summary: Bortezomib for the treatment of progressive multiple myeloma after one prior therapy","volume":"12","author":"Pazdur","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"Suppl 5","key":"121","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.3816\/CLM.2008.s.015","article-title":"Novel therapies for cutaneous t-cell lymphomas","volume":"8","author":"Horwitz","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"122","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase ii trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous t-cell lymphoma","volume":"25","author":"Baccarani","year":"2007","journal-title":"J Clin Oncol"},{"key":"123","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood-2005-09-3731","article-title":"Experience with bortezomib for the treatment of patients with relapsed classical hodgkin lymphoma","volume":"107","author":"Fayad","year":"2006","journal-title":"Blood"},{"key":"124","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.transci.2007.04.009","article-title":"Use of novel proteosome inhibitors as a therapeutic strategy in lymphomas current experience and emerging concepts","volume":"37","author":"Jacobs","year":"2007","journal-title":"Transfus Apher Sci"},{"key":"125","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/10428190701861686","article-title":"Novel anti-myeloma agents and angiogenesis","volume":"49","author":"Terpos","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"126","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V98.2.492","article-title":"Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients","volume":"98","author":"Tricot","year":"2001","journal-title":"Blood"},{"key":"127","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase iii clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the eastern cooperative oncology group","volume":"24","author":"Greipp","year":"2006","journal-title":"J Clin Oncol"},{"key":"128","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","article-title":"Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma","volume":"26","author":"Blade","year":"2008","journal-title":"J Clin Oncol"},{"key":"129","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1097\/MEG.0b013e3283036740","article-title":"Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: A phase i\/ii trial","volume":"20","author":"Peck-Radosavljevic","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"130","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijrobp.2007.09.016","article-title":"A phase iii study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (rtog 0118)","volume":"71","author":"Mehta","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"131","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1080\/10428190701573208","article-title":"Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia","volume":"48","author":"Cooper","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"132","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ygyno.2007.05.013","article-title":"A phase ii trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: A gynecologic oncology group study","volume":"106","author":"Benbrook","year":"2007","journal-title":"Gynecol Oncol"},{"key":"133","first-page":"364","article-title":"[metronomic chemotherapy: A new approach in cancer therapy]","volume":"62","author":"Kalas","year":"2008","journal-title":"Postepy Hig Med Dosw (Online)"},{"key":"134","first-page":"133","article-title":"A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients","volume":"16","author":"Francini","year":"2006","journal-title":"Oncol Rep"},{"key":"135","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10637-008-9137-0","article-title":"Phase i trial of docetaxel and thalidomide: A regimen based on metronomic therapeutic principles","volume":"26","author":"Remick","year":"2008","journal-title":"Invest New Drugs"},{"key":"136","first-page":"831","article-title":"Low-dose oral metronomic chemotherapy prevents mobilization of endothelial progenitor cells into the blood of cancer patients","volume":"22","author":"Peters","year":"2008","journal-title":"In Vivo"},{"key":"137","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s12094-008-0254-7","article-title":"Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer","volume":"10","author":"Alba","year":"2008","journal-title":"Clin Transl Oncol"},{"key":"138","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1200\/JCO.2008.17.4789","article-title":"Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer","volume":"26","author":"Colleoni","year":"2008","journal-title":"J Clin Oncol"},{"key":"139","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.arcmed.2008.05.008","article-title":"Phase ii study of metronomic chemotherapy with thalidomide, carboplatin-vincristine-fluvastatin in the treatment of brain stem tumors in children","volume":"39","author":"de la Cruz-Yanez","year":"2008","journal-title":"Arch Med Res"},{"key":"140","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000119925","article-title":"Antiangiogenic metronomic chemotherapy","volume":"31","author":"Gasparini","year":"2008","journal-title":"Onkologie"},{"key":"141","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes cd4+cd25+ regulatory t cells and restores t and nk effector functions in end stage cancer patients","volume":"56","author":"Chauffert","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"142","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/1078-0432.CCR-08-1507","article-title":"Immunomodulation of foxp3+ regulatory t cells by the aromatase inhibitor letrozole in breast cancer patients","volume":"15","author":"Fox","year":"2009","journal-title":"Clin Cancer Res"},{"key":"143","first-page":"455","article-title":"Metronomic chemotherapy: New rationale for new directions","volume":"7","author":"Andre","journal-title":"Nat Rev Clin Oncol"},{"key":"144","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1158\/1078-0432.CCR-08-1174","article-title":"Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib","volume":"15","author":"Waxman","year":"2009","journal-title":"Clin Cancer Res"},{"key":"145","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1535-6108(03)00336-2","article-title":"Antiangiogenic therapy and tumor progression","volume":"5","author":"Blagosklonny","year":"2004","journal-title":"Cancer Cell"},{"key":"146","first-page":"456","article-title":"Endothelial-derived microparticles: Biological conveyors at the crossroad of inflammation, thrombosis and angiogenesis","volume":"104","author":"Dignat-George","journal-title":"Thromb Haemost"},{"key":"147","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrclinonc.2009.64","article-title":"Branching morphogenesis and antiangiogenesis candidates: Tip cells lead the way","volume":"6","author":"Mazzone","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"148","first-page":"83","article-title":"Vascular integrins: Therapeutic and imaging targets of tumor angiogenesis","volume":"180","author":"Alghisi","journal-title":"Recent Results Cancer Res"},{"key":"149","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1159\/000226221","article-title":"Micromanaging vascular biology: Tiny micrornas play big band","volume":"46","author":"Roy","year":"2009","journal-title":"J Vasc Res"},{"key":"150","first-page":"435","article-title":"Cancer and metastasis: Prevention and treatment by green tea","volume":"29","author":"Mukhtar","journal-title":"Cancer Metastasis Rev"},{"key":"151","first-page":"938","article-title":"Review on molecular and therapeutic potential of thymoquinone in cancer","volume":"62","author":"Mohammad","journal-title":"Nutr Cancer"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.234","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T05:26:29Z","timestamp":1718083589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,7]]},"references-count":151,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["234","21399234"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.234","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,7]]}}}